Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Amgen

Musk Reportedly Suspends Twitter Work On Crypto Wallet, Boeing's Jeppesen Hit By Potential Ransomware Attack, Lyft Cuts Workforce: Top Stories Friday, Nov. 04

Reuters

Benzinga

Looking At Amgen's Recent Unusual Options Activity

Someone with a lot of money to spend has taken a bullish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

1 Biotech Stock to Double Down on in Q4

Leading drug maker Amgen (AMGN) delivered impressive second-quarter results. The company is well-positioned for solid long-term growth, driven by its diversified and growing product portfolio, rising demand from a rapidly aging population, and continued advancements in science and technology. Given its high profitability, attractive dividends, and bright growth prospects, we…

StockNews.com

Amgen is Our Growth Stock of the Week…

Biotech stocks are outperforming due to attractive valuations and strong catalysts. Amgen (AMGN) is one of the top stocks in the space due to its strong product portfolio, pipeline, and impressive management team. Read on to find out why it's our stock of the week.

StockNews.com

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022

Upgrades

Benzinga

Amgen Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 22 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

Benzinga

2 Biotech Stocks to Buy and Hold for the Long Term

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…

StockNews.com

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

Benzinga

5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

StockNews.com

This Is What Whales Are Betting On Amgen

A whale with a lot of money to spend has taken a noticeably bullish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 strange trades.

Benzinga

Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share in cash.

Benzinga

Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday

U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What Are Whales Doing With Amgen

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Gold Tops 1,800; Alibaba Reports Upbeat Results

U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 75 points on Thursday

Benzinga

Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.

Benzinga

Nasdaq Edges Higher; Crude Oil Falls Sharply

U.S. stocks pared some losses midway through trading, with the Nasdaq Composite turning higher on Thursday.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Dow Drops Over 100 Points; U.S. Trade Deficit Shrinks To This Level In June

U.S. stocks traded lower this morning, with the Dow Jones falling more than 100 points on Thursday.

Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Benzinga Before The Bell: Alibaba's Delisting Concerns, Amgen's Potential $10.7B Tax Bill, Kenya Will Not Shut Facebook Services And Other Top Financial Stories Monday, August 1

CNBC

Benzinga

Amgen Whale Trades For July 12

StockNews.com

Amgen is Our Growth Stock of the Week…

Benzinga

Check Out What Whales Are Doing With AMGN

Benzinga

Peering Into Amgen's Recent Short Interest

Amgen's (NASDAQ:AMGN) short percent of float has risen 7.63% since its last report. The company recently reported that it has 20.30 million shares sold short, which is 3.81% of all regular shares that are available for trading.

1 … 5 6 7 8

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Sundar Pichai

584 stories

Jaimini DesaiJaimini Desai

59 stories

Tigran Gambaryan

26 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.